Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin-Metformin vs Sitagliptin-Metformin vs Metformin in Obese Patients With Type 2 Diabetes
NCT07531108Phase 4Completed
- Sponsor
- Hawler Medical University
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hawler Medical University. Primary endpoints: Serum omentin-1 concentrations at 12 weeks and Serum resistin concentrations at 12 weeks. Started Nov 2024; status: completed.
02
Drugs
empagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07531108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531108.